CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.92B, above the global median of $1.18B
- FinancialsAltman Z-Score 8.52: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.32%Below 5Y avg (0.80%)
Annual Rate
CNY 0.04Paid annual
Payout Ratio
28.5%Sustainable
Last Ex-Dividend
Jun 23, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
12.87BCNY1.92B · vs all stocks (USD)
Trailing P/E
90.00xvs Biotechnology peers
Revenue (TTM)
1.53BCNY228.97M · vs all stocks (USD)
Profit Margin
9.38%vs Biotechnology peers
Beta
0.6630xvs all stocks
52-Week Change
30.87%vs all stocks
Market Capitalization
12.87BCNY1.92B · vs all stocks (USD)
Enterprise Value
11.30BCNY1.69B · vs all stocks (USD)
Trailing P/E
90.00xvs Biotechnology peers
Forward P/E
48.75xvs Biotechnology peers
Price to Sales (TTM)
8.46xvs Biotechnology peers
Price to Book (MRQ)
2.36xvs Biotechnology peers
Enterprise to Revenue
7.37xvs Biotechnology peers
Enterprise to EBITDA
36.84xvs Biotechnology peers
Gross Margin
54.28%vs Biotechnology peers
Profit Margin
9.38%vs Biotechnology peers
Operating Margin
6.92%vs Biotechnology peers
Return on Assets (TTM)
0.57%vs Biotechnology peers
Return on Equity (TTM)
2.70%vs Biotechnology peers
Revenue (TTM)
1.53BCNY228.97M · vs all stocks (USD)
Revenue per Share (TTM)
1.36CNYUpdated Sep 21, 2026Quarterly Revenue Growth
53.00%vs Biotechnology peers
Gross Profit (TTM)
806.64MCNY120.46M · vs all stocks (USD)
EBITDA (TTM)
426.91MCNY63.75M · vs all stocks (USD)
Net Income (TTM)
143.79MCNY21.47M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
16.61%vs Biotechnology peers
Operating Cash Flow (TTM)
278.20MCNY41.54M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-53.66MCNY-8.01M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0370CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
0.32%vs all stocks
5-Year Average Dividend Yield
0.80%vs all stocks
Payout Ratio
28.46%vs Biotechnology peers
Minority Interest (Equity)
182.81MCNYFY2025 · Dec 31, 2025Revenue
1.40BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
648.89MCNYFY2025 · Dec 31, 2025Gross Profit
747.53MCNYFY2025 · Dec 31, 2025Operating Income
119.75MCNY17.88M · vs all stocks (USD)
Pre-tax Income
104.62MCNYFY2025 · Dec 31, 2025Income Tax Expense
9.11MCNYFY2025 · Dec 31, 2025Net Income
95.51MCNYFY2025 · Dec 31, 2025EBIT
105.09MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
426.91MCNYFY2025 · Dec 31, 2025Research & Development
131.09MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
368.37MCNYFY2025 · Dec 31, 2025Other Operating Expenses
23.36MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
51.17MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
470.25KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0900CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0900CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.11BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.11BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
95.51MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
4.61MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
75.07MCNYFY2025 · Dec 31, 2025Free Cash Flow
-37.04MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
616.75MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
95.51MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-40.01MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
30.48MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-10.91MCNYFY2025 · Dec 31, 2025Capital Expenditures
-112.10MCNYFY2025 · Dec 31, 2025Net Acquisitions
183.23KCNYFY2025 · Dec 31, 2025Purchase of Investments
-138.25MCNYFY2025 · Dec 31, 2025Sale of Investments
198.31MCNYFY2025 · Dec 31, 2025Other Investing Activity
-153.99MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-205.85MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-15.00MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-33.32MCNYFY2025 · Dec 31, 2025Other Financing Charges
-259.13MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-307.44MCNYFY2025 · Dec 31, 2025Shares Outstanding
1.11BSharesUpdated Sep 21, 2026Float Shares
874.46MSharesUpdated Sep 21, 2026% Held by Insiders
22.45%vs all stocks
% Held by Institutions
9.03%vs all stocks
Total Cash (MRQ)
1.67BCNY249.39M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.53CNYUpdated Sep 21, 2026Total Debt (MRQ)
101.28MCNY15.12M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0183xvs Biotechnology peers
Current Ratio (MRQ)
4.21xvs Biotechnology peers
Book Value per Share (MRQ)
4.96CNYUpdated Sep 21, 2026Total Assets
6.61BCNY987.31M · vs all stocks (USD)
Total Current Assets
2.34BCNYFY2025 · Dec 31, 2025Total Liabilities
1.06BCNYFY2025 · Dec 31, 2025Total Non-current Assets
4.27BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
340.18MCNYFY2025 · Dec 31, 2025Total Current Liabilities
720.53MCNYFY2025 · Dec 31, 2025Cash
1.23BCNYFY2025 · Dec 31, 2025Cash Equivalents
4.18MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.26BCNYFY2025 · Dec 31, 2025Other Short-term Investments
120.11MCNYFY2025 · Dec 31, 2025Accounts Receivable
591.09MCNYFY2025 · Dec 31, 2025Inventory
269.13MCNYFY2025 · Dec 31, 2025Accounts Payable
256.02MCNYFY2025 · Dec 31, 2025Short-term Debt
1.43MCNYFY2025 · Dec 31, 2025Other Current Liabilities
7.54MCNYFY2025 · Dec 31, 2025Long-term Debt
146.69KCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.11BCNYFY2025 · Dec 31, 2025Retained Earnings
3.24BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
5.55BCNY828.91M · vs all stocks (USD)
Treasury Stock
242.30MCNYFY2025 · Dec 31, 202552-Week Low
8.61CNYUpdated Sep 21, 202652-Week High
19.00CNYUpdated Sep 21, 202652-Week Change
30.87%vs all stocks
Beta
0.6630xvs all stocks
50-Day MA
12.40CNYUpdated Sep 21, 2026200-Day MA
14.08CNYUpdated Sep 21, 2026Avg 10-Day Volume
9.60MSharesUpdated Sep 21, 2026Avg 30-Day Volume
12.28MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
0.1300CNYUpdated Sep 21, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 8.52: safe zoneNotable
Altman Z-Score: 8.52
High earnings qualityNotable
Earnings Quality Score: 0.53
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.92B, above the global median of $1.18BNotable
Market cap (USD): 1,921,751,000.372Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Innostar Bio-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineSenseMakingRule
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ChemoMetec A/S
Tier 1ProductionApproval-Gated PipelineRule
OneSource Specialty Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zymeworks Inc.
Tier 1ProductionApproval-Gated PipelineRule
Xencor Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Agios Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Nektar Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Inner Mongolia Furui Medical Science Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Cec Environmental Protection Co. Ltd.
1 interpretationHigh Retained Earnings With Profitability And Equity
Qingdao Eastsoft Communication Co., Ltd.
1 interpretationHigh Retained Earnings With Profitability And Equity
Edan Instruments Inc.
1 interpretationHigh Retained Earnings With Profitability And Equity